Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03620747 · ClinicalTrials.gov registry record · Phase 3
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 393
- Enrollment target
NCT03620747 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 393 participants.
The verdict
NCT03620747, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 393 participants
- Enrollment target
Study Summary
Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).
Interventions
- DRUG Dupilumab SAR231893 (REGN668)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03620747
The ClinicalTrials.gov registry entry for NCT03620747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab SAR231893 (REGN668) is the first listed.
NCT03620747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03620747 about?
NCT03620747 is a clinical study titled "Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)". Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).
What is the current status of trial NCT03620747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 393 participants. The study started on 2018-08-30. Estimated completion is 2022-02-18.
What interventions are being tested in trial NCT03620747?
The interventions under investigation include: Dupilumab SAR231893 (REGN668) (DRUG).
Who is sponsoring clinical trial NCT03620747?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.